Free Trial

Seer Q2 2023 Earnings Report

Seer logo
$2.26 -0.03 (-1.31%)
As of 02/21/2025 04:00 PM Eastern

Seer EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Seer Revenue Results

Actual Revenue
$4.01 million
Expected Revenue
$5.40 million
Beat/Miss
Missed by -$1.39 million
YoY Revenue Growth
N/A

Seer Announcement Details

Quarter
Q2 2023
Time
N/A

SEER Upcoming Earnings

Seer will be holding an earnings conference call on Thursday, February 27 at 4:30 PM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

Conference Call Audio

Seer Earnings Headlines

What Is the ‘Seer’ Twist on ‘The Traitors’?
Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
See More Seer Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Seer? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seer and other key companies, straight to your email.

About Seer

Seer (NASDAQ:SEER), a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

View Seer Profile

More Earnings Resources from MarketBeat